A phase Ib/II trial investigating the combination of Tagrisso (osimertinib) and inhibitor G1T38 for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC)

Trial Profile

A phase Ib/II trial investigating the combination of Tagrisso (osimertinib) and inhibitor G1T38 for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC)

Planning
Phase of Trial: Phase I/II

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs G1T 38 (Primary) ; Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors G1 Therapeutics
  • Most Recent Events

    • 30 Nov 2017 New trial record
    • 28 Nov 2017 According to a G1 Therapeutics media release, the company plans to initiate this trial in the first quarter of 2018.
    • 08 Nov 2017 According to a G1 Therapeutics media release, the company has submitted an Investigational New Drug (IND) application to the US FDA for G1T38 and Tagrisso combination in non-small cell lung cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top